Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1401 - Heath related quality of life (HRQOL) assessment for patients with advanced renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitor (TKI) using electronic patient reported outcome (PRO) in daily clinical practice


10 Sep 2017


Poster display session


Cytotoxic Therapy;  Supportive Care and Symptom Management;  Renal Cell Cancer


Guillaume Mouillet


Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388


G. Mouillet1, A. Pozet1, J. Fritzsch1, I. Es-Saad1, S. Paget-Bailly1, A. Foubert1, D. Berthod2, A. Anota1, F. Bonnetain1, A. Thiery-Vuillemin3

Author affiliations

  • 1 Methodological And Quality Of Life Unit In Oncology (inserm Umr 1098), University Hospital Jean Minjoz, 25000 - Besançon/FR
  • 2 Medical Oncology, Besancon University Hospital, 25000 - Besançon/FR
  • 3 Medical Oncology, University Hospital Jean Minjoz, 25000 - Besançon/FR


Abstract 1401


In mRCC, two therapies are mainly used in first line setting: pazopanib and sunitinib. These two TKI are equally effective in terms of survival however they are responsible for frequent adverse events. Physician mainly use RECIST progression-free survival (PFS) and NCI CTCAE safety as a guide to evaluate treatment efficiency and tolerance. In contrast HRQOL assessment is often restricted to clinical trial. It could be of particular interest to evaluate HRQOL in daily clinical practice in order to adequately choose and manage therapy. Currently the development of Information and Communication Technology may allow HRQOL monitoring in routine practice. The objective of the QUANARIE Study is to evaluate the feasibility of HRQOL assessment in daily clinical practice for patients with mRCC treated with TKI using electronic PRO.

Trial design

QUANARIE study (NCT03062410) is an interventional, prospective, multicenter trial involving 9 french oncological centers. Patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation. Primary objective is to assess the feasibility of routine assessment of HRQOL evaluated by the rate of filled questionnaires at 12-months. Key secondary objectives are: exhaustiveness, acceptability and effectiveness. Physician's satisfaction with electronic HRQOL evaluation will be assessed. We hypothesized that 80% of filled questionnaires at 12-months would be meaningful. A sample size of 56 patients would be needed. Enrollment is expected to last for 6 mo. Study started in April 2017. Update will be display on poster during ESMO congress.

Clinical trial identification


Legal entity responsible for the study

University Hospital Jean Minjoz




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.